A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2

Cancer

Volumn 82, Issue 2, 1998, Pages 403-411

  Raad, Issam I ^a   Hachem, Ray Y ^a   Abi Said, Dima ^a   Rolston, Kenneth V I ^a   Whimbey, Estella ^a   Buzaid, Antonio C ^a   Legha, Sewa ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antibiotic prophylaxis; Catheter related infection; Interleukin 2; Melanoma; Novobiocin; Rifampin

Indexed keywords

INTERLEUKIN 2; NOVOBIOCIN; RIFAMPICIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD VESSEL CATHETERIZATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HIGH RISK POPULATION; HUMAN; MELANOMA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTEREMIA; BACTERIAL INFECTIONS; BIOLOGICAL RESPONSE MODIFIERS; CATHETERIZATION, CENTRAL VENOUS; CATHETERIZATION, PERIPHERAL; CATHETERS, INDWELLING; CHEMOPREVENTION; CROSS-OVER STUDIES; EQUIPMENT CONTAMINATION; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NAUSEA; NOVOBIOCIN; PROSPECTIVE STUDIES; RIFAMPIN; VOMITING;

EID: 0031984930     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980115)82:2<412::AID-CNCR22>3.0.CO;2-0     Document Type: Article

References (36)

1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and IL-2 or high IL-2 dose alone. N Engl J Med 1987;316:889-97.
2. Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, et al. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 1994;9:103-11.
3. Khayat D, Borel C, Tourani J, Benhammouda A, Antoine E, Rixe O, et al. Highly active chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-80.
4. Richards J, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-43.
5. Buzaid AC, Legha SS. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 1994;21(Suppl 14):23-8.
6. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995;332:567-75.
7. Margolin K, Jaffe HS, Hawkins M, Atkins BM, Ciobanu N, Creekmore S, et al. Toxicity of interleukin-2 (IL-2) and lymphokine activated killer (LAK) cell therapy [abstract no. 988]. Proc Am Soc Clin Oncol 1987;6:251.
8. Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR, MacFarlane MP, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994;12:2714-22.
9. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990;322:959-65.
10. Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, Atkins MB. Nosocomial sepsis associated with interleukin-2. Ann Intern Med 1990;112:102-7.
11. Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenbert SA. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol 1993;11:136-47.
12. Richards JM, Gilewski TA, Vogelzang NJ. Association of interleukin-2 therapy with staphylococcal bacteremia. Cancer 1991;67:1570-5.
13. Lim SH, Giles FJ, Smith MP, Goldston AH. Bacterial infections in lymphoma patients treated with recombinant interleukin-2. Acta Haematol 1991;85:135-8.
14. Bock SN, Lee RE, Fisher B, Rubin JT, Schwartzentruber DJ, Wei JP, et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 1990;8:161-9.
15. Hartmann LC, Urba WJ. Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients. J Natl Cancer Inst 1989; 81:1190-2.
16. Walsh TJ, Hansen SL, Tatem BA, Auger F, Standiford HC. Activity of novobiocin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1985;15:435-40.
17. Dixson S, Brumfitt W, Hamilton-Miller JMT. In vitro activity of combinations of antibiotics against Staphylococcus aureus resistant to gentamicin and methicillin. Infection 1985;13:43-6.
18. Dixson S, Brumfitt W, Hamilton-Miller JMT. Activity of rifampicin against staphylococci, with special reference to multiresistant strains. J Antimicrob Chemother 1984; 13(Suppl C):7-16.
19. Proctor RA, Wick P, Hamill RJ, Horstmeier P, Gullings-Handley J, Weisensel M, et al. In vitro studies of antibiotic combinations for multiply-resistant coagulase-negative staphylococci. J Antimicrob Chemother 1987;20:223-31.
20. Arathoon EG, Hamilton JR, Hench CE, Stevens DA. Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates. Antimicrob Agents Chemother 1990;34:1655-9.
21. Darouiche RO, Raad II, Bodey GP, Musher DM. Antibiotic susceptibility of staphylococcal isolates from patients with vascular catheter-related bacteremia: potential role of the combination of minocycline and rifampin. Int J Antimicrob Agents 1995;6:31-6.
22. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP. Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother 1995;39:2397-400.
23. Maki DG, Weise CE, Sarafin HW. A semiquantitative method for identifying intravenous catheter-related infection. N Engl J Med 1977;296:1305-9.
24. Raad II, Baba M, Bodey GP. Diagnosis of catheter-related infections: the role of surveillance and targeted quantitative skin cultures. Clin Infect Dis 1995;20:593-7.
25. Kloos WE, Wolfsbohl JF. Identification of Staphylococcus species with the API STAPH-IDENT System. J Clin Microbiol 1982;16:509-16.
26. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that are grown aerobically. 2nd edition. Approved Standard M7-A2. Villanova, PA: NCCLS, 1990.
27. Legha S, Buzaid AC, Ring S, Bedikian A, Plager C, Eaton O, et al. Improved results of treatment of metastatic melanoma with combined use of biotherapy and chemotherapy [abstract no. 1343]. Proc Am Soc Clin Oncol 1994;13:394.
28. Murphy PM, Lane HC, Gallin JL, Fauci AS. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-γ. Ann Intern Med 1988;108:36-41.
29. Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, et al. Induction of circulating tumor necrosis factor (TNF-alpha) as the mechanism for febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988;8:426-36.
30. Atkinson YH, Marasco WA, Lopez AF, Vadas MA. Recombinant tumor necrosis factor-alpha: regulation of N-formyl-methionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin Invest 1988;81:759-65.
31. Orcese C, Borri A, Besana C. Antibiotic prophylaxis to prevent catheter-related infections in recombinant interleukin-2 treated patients. J Clin Oncol 1990;8:1767-9.
32. Farber BF, Kaplan MH, Clogston AG. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis 1990;161:37-40.
33. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-12.
34. Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993;20:27-32.
35. Raad I, Darouiche R, Hachem R, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 1996;173:418-24.
36. Darouiche RO, Raad II, Wall M, Gabrielli A, Huaringa A, Price K, et al. Antimicrobial efficacy, durability and safety of central venous catheters coated with minocycline and rifampin [abstract]. Crit Care Med 1996;24(Suppl):A121.